Search
Inovio Pharmaceuticals Inc
INOAdd to Watchlist
1.220USD
+0.030+2.52%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
84.18MMarket Cap
LossP/E TTM
More Details of Inovio Pharmaceuticals Inc Company
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Inovio Pharmaceuticals Inc Info
Ticker SymbolINO
Company nameInovio Pharmaceuticals Inc
IPO dateDec 08, 1998
CEOShea (Jacqueline Elizabeth)
Number of employees134
Security typeOrdinary Share
Fiscal year-endDec 08
Address660 W. Germantown Pike
CityPLYMOUTH MEETING
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19462
Phone18584103134
Websitehttps://www.inovio.com/
Ticker SymbolINO
IPO dateDec 08, 1998
CEOShea (Jacqueline Elizabeth)
Company Executives of Inovio Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
111.02K
+23.43%
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
87.59K
--
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
46.82K
+14.79%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
43.23K
+14.37%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
--
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
8.92K
--
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
8.73K
--
Dr. Ann Calby Miller, M.D.
Dr. Ann Calby Miller, M.D.
Independent Director
Independent Director
--
--
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
111.02K
+23.43%
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
87.59K
--
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
46.82K
+14.79%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
43.23K
+14.37%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
--
FAQs
Who are the top five shareholders of Inovio Pharmaceuticals Inc?
The top five shareholders of Inovio Pharmaceuticals Inc are: Dr. Jacqueline Elizabeth Shea, Ph.D.
How many institutions hold shares of Inovio Pharmaceuticals Inc (INO)?
As of 2026Q1, 266 institutions hold shares of Inovio Pharmaceuticals Inc, with a combined market value of approximately 32.85M, accounting for 40.31% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 3035014.00.